Kolon TissueGene Valuation

Is A950160 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A950160 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A950160's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A950160's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A950160?

Key metric: As A950160 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A950160. This is calculated by dividing A950160's market cap by their current book value.
What is A950160's PB Ratio?
PB Ratio	n/a
Book	₩0
Market Cap	₩1.37t

A950160 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does A950160's PB Ratio compare to its peers?

The above table shows the PB ratio for A950160 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	256.2x
A298380 ABL Bio	995.4x	54.8%	₩1.5t
A006280 GC Biopharma	1.2x	104.4%	₩1.5t
A007390 NatureCellLtd	27.3x	n/a	₩1.7t
A096530 Seegene	1x	27.2%	₩1.0t
A950160 Kolon TissueGene	n/a	n/a	₩1.4t

Price-To-Book vs Peers: Insufficient data to calculate A950160's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Book Ratio vs Industry

How does A950160's PB Ratio compare vs other companies in the KR Biotechs Industry?

5 Companies	Price / Book	Estimated Growth	Market Cap

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: Insufficient data to calculate A950160's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is A950160's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A950160 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	n/a
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A950160's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩282,000.00

6.8%

76.9%

J2KBIO

₩52.9b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,210.00

-5.0%

n/a

Medy-Tox

₩883.1b

Operates as a biopharmaceutical company in South Korea.

A086900

₩132,000.00

3.4%

-38.6%